FAQ: eXoZymes' Cell-Free Biomanufacturing Partnership with B2i Digital
Summary
eXoZymes Inc. has partnered with B2i Digital to showcase its cell-free, AI-guided enzyme platform that provides a scalable alternative to petrochemical processes and traditional synthetic biology. This collaboration aims to increase visibility among investors for what the company calls the next generation of sustainable biomanufacturing.
What is the main purpose of the partnership between eXoZymes and B2i Digital?
The partnership aims to showcase eXoZymes’ cell-free, AI-guided enzyme platform to B2i Digital’s investor community and enhance the company’s visibility among investors who understand the value of scalable enzyme-based alternatives to traditional manufacturing methods.
What is eXoZymes’ core technology and how does it work?
eXoZymes develops a cell-free, AI-guided enzyme platform that uses advanced enzymes called exozymes, which are enhanced through AI and bioengineering to thrive in bioreactors without living cells, transforming biomass into natural products, medicines, chemicals, and biofuels.
Why is eXoZymes’ technology considered significant for biomanufacturing?
It represents a historic first in biomanufacturing by freeing enzyme-driven chemical reactions from cellular limitations, offering a scalable, lower-impact alternative to petrochemical processes, natural extraction, and traditional synthetic biology while addressing scale-up bottlenecks.
What types of products does eXoZymes initially target with its technology?
The company initially targets low volume/high value natural products like NCT, with potential for pharmaceutical applications, providing a commercially viable path to scalable production of small molecules at industrial scale.
Who are the key executives involved in this partnership?
David Shapiro is the CEO of B2i Digital, and Michael Heltzen is the CEO of eXoZymes, both of whom have expressed enthusiasm about the collaboration and its potential to communicate the commercial value of cell-free biomanufacturing.
How does eXoZymes’ approach compare to traditional manufacturing methods?
The platform offers a scalable, lower-impact alternative to petrochemical processes, natural extraction, and first-generation synthetic biology by using cell-free enzymes that operate without living cells, providing more efficient and sustainable production pathways.
What is B2i Digital’s role and expertise in this partnership?
B2i Digital partners with companies through its Featured Company program, using digital marketing technology and capital markets expertise to provide institutional-quality exposure to growth companies through its network of over 1.4 million market participants.
When was this partnership announced and what is the current status?
The partnership was announced on October 14, 2025, with eXoZymes being named a B2i Digital Featured Company to enhance its visibility among the investment community.
How can interested parties contact B2i Digital for more information?
Contact David Shapiro, CEO of B2i Digital, at 212.579.4844 or [email protected], or visit their website at https://b2idigital.com and their social media profiles on LinkedIn, X, Facebook, Instagram, and YouTube.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at NewMediaWire
Article Control ID: 252441